NewAmsterdam Pharma Company N.V. Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
NewAmsterdam Pharma Company N.V. (NAMS) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of -EUR 65.00 thousand for the 12-month period ending 2022-12-31, per its 20-F/A filed 2024-10-28.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2024-10-28
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2022-12-31 | -65.00K EUR 20-F/A · filed 2024-10-28 |
| 2021-12-31 | -10.00K EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |